Rapport
3-MMC. Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)
Auteur(s) :
OEDT = EMCDDA (Observatoire européen des drogues et des dépendances = European monitoring centre for drugs and drug addiction)
Année :
2022
Page(s) :
131 p.
Langue(s) :
Anglais
Éditeur(s) :
Lisbon : OEDT / EMCDDA
Collection :
Risk assessments
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Organismes
OEDT
Thésaurus mots-clés
CONTROLE DES STUPEFIANTS
;
PHARMACOLOGIE
;
FACTEUR DE RISQUE
;
TOXICOLOGIE
;
CATHINONES
;
REGLEMENTATION
;
DROGUES DE SYNTHESE
;
CHIMIE
;
TOXICITE
Note de contenu :
TABLE OF CONTENTS:
- EMCDDA Initial Report on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC).
- Risk assessment report on a new psychoactive substance: 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC).
- Annex 1: Technical report on the new psychoactive substance 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC).
- Annex 2: Participants of the risk assessment meeting, 18 November 2021.
- EMCDDA Initial Report on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC).
- Risk assessment report on a new psychoactive substance: 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC).
- Annex 1: Technical report on the new psychoactive substance 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC).
- Annex 2: Participants of the risk assessment meeting, 18 November 2021.
Résumé :
This publication presents the data and findings of the risk assessment on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2021. On the basis of the Risk Assessment Report, on 18 March 2022, the Commission decided that 3-MMC should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA.
Autre(s) lien(s) :
News release (18/03/2022)
- voir aussi :